Antibodies in alloimmunized uraemic patients treated with recombinant erythropoietin

Transpl Int. 1994;7 Suppl 1:S290-3. doi: 10.1111/j.1432-2277.1994.tb01370.x.


We have retrospectively analysed sera from 52 already sensitized uraemic patients collected over 1 year and compared erythropoietin (EPO)-treated with non-EPO-treated patients. Significantly fewer (P<0.01) patients (33%) on dialysis because of the rejection of their kidney grafts received EPO than patients on dialysis because of underlying kidney disease (71%). EPO treatment reduced the number of additional blood transfusions, since 3/28 EPO-treated but 12/24 non-EPO-treated patients were given blood (P<0.05). Among the EPO-treated patients, 64% showed a loss of panel-reactive antibodies (PRA), as measured by the micro-lymphocytotoxic technique, while only 12.5% of the non-treated patients showed a loss of PRA (P<0.01). In the subgroup of transplanted patients, PRA loss was only found among the EPO-treated patients, but their number was small (P<0.05). The class, subclass and specificities of the antibodies, as determined by FACS (flow cytometry) analyses, showed no distinct differences between EPO- and non-EPO-treated patients. The differences were significant between transfused and previously transplanted patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia / prevention & control
  • Antibodies / blood*
  • Erythropoietin / therapeutic use*
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin M / blood
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / immunology*
  • Kidney Transplantation / immunology
  • Peritoneal Dialysis, Continuous Ambulatory
  • Recombinant Proteins
  • Renal Dialysis
  • Retrospective Studies
  • T-Lymphocytes, Cytotoxic / immunology
  • Uremia / complications
  • Uremia / drug therapy*
  • Uremia / immunology


  • Antibodies
  • Immunoglobulin A
  • Immunoglobulin M
  • Recombinant Proteins
  • Erythropoietin